001     132559
005     20240229105023.0
024 7 _ |a 10.1007/s11427-017-9138-9
|2 doi
024 7 _ |a pmid:29307109
|2 pmid
024 7 _ |a 1006-9305
|2 ISSN
024 7 _ |a 1674-7305
|2 ISSN
024 7 _ |a 1862-2798
|2 ISSN
024 7 _ |a 1869-1889
|2 ISSN
024 7 _ |a altmetric:31401072
|2 altmetric
037 _ _ |a DKFZ-2018-00237
041 _ _ |a eng
082 _ _ |a 570
100 1 _ |a Lv, Na
|b 0
245 _ _ |a miR-137 inhibits melanoma cell proliferation through downregulation of GLO1.
260 _ _ |a Heidelberg
|c 2018
|b Springer37831
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1663742415_16521
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2018 May;61(5):541-549
520 _ _ |a Late-stage melanoma is refractory to current therapies. MicroRNAs (miRNAs) can modulate many physiological and pathological processes of melanoma. Studies have demonstrated that miR-137 acts as a tumor suppressor by inhibiting the proliferation of melanoma cells through targeting multiple mRNAs. The glyoxalase system member glyoxalase 1 (GLO1) is the principal scavenging enzyme of methylglyoxal (MG), a toxic byproduct of glycolysis. Using35S in vivo/vitro labelling analysis for dynamic proteomics (SiLAD), we found that miR-137 downregulated the expression of GLO1 in melanoma cells. Bioinformatics analysis predicted that GLO1 is a direct target of miR-137. This was validated by dual luciferase reporter assay. Quantitative RT-PCR (qRT-PCR) and western blot analysis indicated that miR-137 could decrease endogenous GLO1 expression. Furthermore, siRNA targeting of GLO1 mimicked inhibition of melanoma cell proliferation caused by miR-137 overexpression. Re-expression of GLO1 was able to restore miR-137-mediated suppression of melanoma cell proliferation. Therefore, these results suggest that miR-137 inhibits the proliferation of melanoma cells by targeting GLO1.
536 _ _ |a 317 - Translational cancer research (POF3-317)
|0 G:(DE-HGF)POF3-317
|c POF3-317
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Hao, Shuai
|b 1
700 1 _ |a Luo, Chonglin
|b 2
700 1 _ |a Abukiwan, Alia
|0 P:(DE-He78)ee782484657011f0081a1425afa47a3f
|b 3
|u dkfz
700 1 _ |a Hao, Ying
|b 4
700 1 _ |a Gai, Fei
|b 5
700 1 _ |a Huang, Weiwei
|b 6
700 1 _ |a Huang, Lingyun
|b 7
700 1 _ |a Xiao, Xueyuan
|b 8
700 1 _ |a Eichmüller, Stefan
|0 P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944
|b 9
|u dkfz
700 1 _ |a He, Dacheng
|b 10
773 _ _ |a 10.1007/s11427-017-9138-9
|0 PERI:(DE-600)2133225-3
|n 5
|p 541-549
|t Science in China / C
|v 61
|y 2018
|x 1869-1889
909 C O |p VDB
|o oai:inrepo02.dkfz.de:132559
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)ee782484657011f0081a1425afa47a3f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-317
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Translational cancer research
|x 0
914 1 _ |y 2018
915 _ _ |a Allianz-Lizenz / DFG
|0 StatID:(DE-HGF)0400
|2 StatID
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b SCI CHINA LIFE SCI : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-He78)G182-20160331
|k G182
|l GMP Einheit Zelluläre Therapie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)G182-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21